Skip to Main Content

Paper Details

Analysis and therapeutic targeting of the IL-1R pathway in anaplastic large cell lymphoma.
Blood
1
2023
A20 loss-of-function mutation, ALCL, ALCL cell lines, ALCLs, ALK, ALK+, ALK- ALCLs, Anaplastic large cell lymphoma, CD30, IL-1, IL-1R, IRAK1, JAK, JAK2, STAT3, anaplastic, anaplastic large cell lymphoma, anaplastic lymphoma, cell line, interleukin-1R, mature T-cell neoplasms, mouse, pC, pC ALK- ALCL, pC-, pC-ALCL, pC-ALCL lines, pacritinib, primary cutaneous, primary cutaneous (pC), primary cutaneous (pC) ALK- ALCLs, tumors
Author NameAffiliation
Wei WeiFox Chase Cancer Center
Wenming XiaoCenter for Drug Evaluation and Research
Wenming XiaoCenter for Drug Evaluation and Research
Louis M StaudtNational Cancer Institute, National Institutes of Health
Louis M StaudtNational Cancer Institute, National Institutes of Health
  • 1 - 5

Datasets

Release 1.2